Meropenem + Fosfomycin
ApprovedSmall molecule
Meropenem + Fosfomycin is one of 11 small molecule programs targeting Gram-Negative Bacterial Infections. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Gram-Negative Bacterial Infections
#DrugCompanyPhaseTrials
1Fetroja
ShionogiApproved
Avycaz
PPhiladelphia Eye Associates
Approved
Ceftazidime-Avibactam
PfizerApproved
Tygacil
PPrism Pharmaceuticals
Approved
Merrem
BB. Braun Medical Inc.
Approved
Ceftolozane-Tazobactam
TTemple University
Approved
Meropenem-Vaborbactam
MMelinta Therapeutics, Inc.
Approved
Meropenem + Fosfomycin
NNational University of Singapore
Approved
Primaxin
PfizerPreclinical
ATM-AVI
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Meropenem + Fosfomycin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- NNational University of Singapore